JP2015535252A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535252A5
JP2015535252A5 JP2015539755A JP2015539755A JP2015535252A5 JP 2015535252 A5 JP2015535252 A5 JP 2015535252A5 JP 2015539755 A JP2015539755 A JP 2015539755A JP 2015539755 A JP2015539755 A JP 2015539755A JP 2015535252 A5 JP2015535252 A5 JP 2015535252A5
Authority
JP
Japan
Prior art keywords
indazole
sulfonamide
fluoro
alkyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535252A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066360 external-priority patent/WO2014066491A1/en
Publication of JP2015535252A publication Critical patent/JP2015535252A/ja
Publication of JP2015535252A5 publication Critical patent/JP2015535252A5/ja
Pending legal-status Critical Current

Links

JP2015539755A 2012-10-26 2013-10-23 電位作動型ナトリウムチャネルにおいて選択的活性を有するn−置換インダゾールスルホンアミド化合物 Pending JP2015535252A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719118P 2012-10-26 2012-10-26
US61/719,118 2012-10-26
PCT/US2013/066360 WO2014066491A1 (en) 2012-10-26 2013-10-23 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

Publications (2)

Publication Number Publication Date
JP2015535252A JP2015535252A (ja) 2015-12-10
JP2015535252A5 true JP2015535252A5 (enExample) 2016-12-08

Family

ID=50545213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539755A Pending JP2015535252A (ja) 2012-10-26 2013-10-23 電位作動型ナトリウムチャネルにおいて選択的活性を有するn−置換インダゾールスルホンアミド化合物

Country Status (10)

Country Link
US (1) US9388179B2 (enExample)
EP (1) EP2911663B1 (enExample)
JP (1) JP2015535252A (enExample)
KR (1) KR20150074123A (enExample)
CN (1) CN104869992A (enExample)
AU (1) AU2013334664A1 (enExample)
BR (1) BR112015008987A2 (enExample)
CA (1) CA2891056A1 (enExample)
RU (1) RU2015119640A (enExample)
WO (1) WO2014066491A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
MX2017011652A (es) * 2015-03-13 2018-02-09 Abbvie Inc (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック, インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
EP3390374B1 (en) 2015-12-18 2020-08-26 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
CA3023465C (en) 2016-05-20 2024-09-24 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
AU2017371674B2 (en) 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
CN107247885B (zh) * 2017-07-06 2020-07-03 中国水产科学研究院黄海水产研究所 一种电压-门控钠离子通道的结构预测方法
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MA53489A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
WO2020192553A1 (zh) * 2019-03-22 2020-10-01 上海海雁医药科技有限公司 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途
WO2023154913A1 (en) 2022-02-14 2023-08-17 Arase Therapeutics Inc. Inhibitors of parg
CN119095828A (zh) * 2022-03-31 2024-12-06 江苏恒瑞医药股份有限公司 吲唑类化合物、其制备方法及其在医药上的应用
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
US4242273A (en) 1977-09-27 1980-12-30 American Cyanamid Company 4-(Monoalkylamino)benzoic acid amides and imidates
US4136256A (en) 1977-09-27 1979-01-23 American Cyanamid Company 4-(monoalkylamino)benzoic acid imidates
US4309553A (en) 1977-09-27 1982-01-05 American Cyanamid Company Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent
US4272546A (en) 1977-12-19 1981-06-09 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4254138A (en) 1977-12-19 1981-03-03 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4243609A (en) 1978-02-02 1981-01-06 American Cyanamid Company Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds
US4230878A (en) 1978-03-08 1980-10-28 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives
US4211783A (en) 1978-03-20 1980-07-08 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds
US4227014A (en) 1978-02-27 1980-10-07 American Cyanamid Company 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof
US4230628A (en) 1978-04-12 1980-10-28 American Cyanamid Company 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs
US4245097A (en) 1978-02-27 1981-01-13 American Cyanamid Company 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents
US4205085A (en) 1978-03-09 1980-05-27 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds
US4318914A (en) 1978-03-09 1982-03-09 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4310545A (en) 1978-03-09 1982-01-12 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds
US4305959A (en) 1978-03-09 1981-12-15 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4485105A (en) 1978-10-12 1984-11-27 American Cyanamid Company Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides
DK471479A (da) 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US4670421A (en) 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
JP2008540539A (ja) * 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
WO2010047990A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic m1 receptor positive allosteric modulators
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドPfizer Limited 化合物
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2638505B1 (en) 2010-11-10 2019-04-24 Datalogic USA, Inc. Adaptive data reader and method of operating
WO2012095781A1 (en) * 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
JP2014521749A (ja) 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors

Similar Documents

Publication Publication Date Title
JP2015535252A5 (enExample)
RU2015119640A (ru) Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
ES2535290T3 (es) Compuestos de isoindolina sustituidos en posición 5
ES2726946T3 (es) Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
JP5886411B2 (ja) 新規のピリミジン誘導体
US20190365772A1 (en) Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
US20250115563A1 (en) Modulators of the integrated stress pathway
AU2018360850A1 (en) Modulators of the integrated stress pathway
JP2004521095A5 (enExample)
JP2006515858A5 (enExample)
RU2000105266A (ru) Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца
CA2430579A1 (en) Isoindolin-1-one glucokinase activators
RU2003120512A (ru) Активаторы изоиндолин-1-он-глюкокиназы
AR089134A1 (es) Arilos y heteroarilos biciclicos inhibidores de los canales de sodio
TW201922251A (zh) 抗癌劑
ES2768399T3 (es) Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
CA2982890A1 (en) Plk4 inhibitors
JP2025512963A (ja) ケモカイン受容体モジュレータ及びその使用
CN101578277A (zh) 5-取代的异二氢吲哚化合物
BR112021012138A2 (pt) Análogos de pentamidina e seus usos
RU2018107581A (ru) Новые ингибиторы cdk8/19
JP2012519668A5 (enExample)
US12215094B2 (en) Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
HK40037526B (en) Modulators of the integrated stress pathway